Semiquantitative CLDN18 expression and clinical outcomes in patients with CLDN18-positive gastric cancer treated with zolbetuximab plus chemotherapy

Background: Zolbetuximab plus chemotherapy improves survival in patients with human epidermal growth factor receptor 2 (HER2)-negative, claudin 18 (CLDN18)-positive advanced gastric cancer (AGC), which is defined as ≥75% of tumor cells with moderate-to-strong membranous staining. Whether semiquantit...

ver descrição completa

Detalhes bibliográficos

Principais autores:	A. Ooki, K. Nakano, K. Shimozaki, M. Takamatsu, S. Fukuoka, S. Sakata, H. Osumi, K. Yoshikawa, E. Toyokawa, K. Yoshino, S. Udagawa, T. Wakatsuki, M. Ogura, E. Shinozaki, K. Chin, H. Kawachi, K. Yamaguchi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-03-01
Colecção:	ESMO Gastrointestinal Oncology
Assuntos:	gastric cancer claudin 18 zolbetuximab biomarker
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S294981982600004X
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!